Tryp Therapeuatics (TRYPF) Coverage Report

While the effects of classic hallucinogens generally begin within 20 to 90 minutes and can last as long as 12 hours (e.g., LSD) or as short as 15 minutes in others (synthetic DMT), the effects from dissociative drugs can begin within a few minutes and last a few hours. Psychedelics’ mechanism of action. As mentioned in our Executive Summary, there has been an increasing number and quality of research papers that review potential therapeutic applications of hallucinogenic drugs (Exp Clin Psychopharmacol. 2016 Aug; 24(4): 229–268; Am J Psychiatry. 2020 May 1;177(5):391-410; CNS Drugs. 2020 Sep;34(9):925-946). These and other peer-reviewed papers document psychedelics’ promise in treating a range of psychological disorders where current treatments are often insufficient, including depression, substance use, anxiety disorders, and many others. We are most interested in the most untreated conditions, some of which are being addressed by TRP-8803. Interestingly, we’ve noticed the benefits of hallucinogens are similar to other hallucinogens, despite their different sources (natural or synthetic, for example). These include empathogens/entactogens, dissociatives, or atypical hallucinogens (Exp Clin Psychopharmacol. 2016 Aug; 24(4): 229–268). Here, we summarize some of the key findings of recent research into psychedelics, with a focus on their mechanism of action. Exhibit 8: Randomized clinical trial outcomes of psychedelics, by type, including five key measures. Source: Am J Psychiatry. 2020 May 1;177(5):391-410 NYU Professor Collin Reiff and colleagues conducted a meta-analysis on all hallucinogens by reviewing 1,603 sources published between 2007 and 2019 (Am J Psychiatry 2020; 177:391–410). The researchers found compelling clinical evidence that support the use of MDMA in the treatment of PTSD (Eur J Psychotraumatol. 2021; 12(1): 1853379) and psilocybin in the treatment of cancer-related anxiety (Psychopharmacol 2016; 30: 1165-1180) and major depressive disorder (JAMA Psychiatry 2021; 78: 481- 489) and These researchers went on to support the use of LSD and ayahuasca in the treatment of psychiatric disorders, although the evidence again deemed too early. Further details are summarized in the papers’ table (see Exhibit 8). Defining outcomes and environments from psychedelic assisted therapies. “Psychedelic-assisted psychotherapy” is a variable course of therapy that involves the Michael Higgins 212.409.2074 Tryp Therapeutics, Inc. (TRYPF) Page 15